In brief: Sirtex, Imugene, Biosignal, Uscom

By Staff Writers
Monday, 08 November, 2004

Cancer technology specialist Sirtex (ASX:SRX) has firmed new distribution deals in Israel and India for its targeted radioactive particle liver cancer treatment, SIR-Spheres, which has recently won regulatory approval in both markets.

The company has also named a distributor for Hong Kong and China, where it has won regulatory approval to conduct clinical trials. Sirtex said it regarded the Indian and Chinese markets as small in comparison with its North American and European opportunities, because of the high cost of the treatment.

Imugene

Paul MacLernan has moved from his position as head of Agenix' global health business to become Imugene's (ASX:IMU) chief operating officer.

MacLernan restructured Agenix' animal health business, and brought in increased sales with new distributor agreements - the right touch, Imugene said, for its business as it began to roll out its receptor mimic technology and adenoviral vector delivery system around the world.

Imugene also appointed Dr Peter Claxton as regulatory affairs consultant.

Biosignal

Biosignal (ASX:BOS) has engaged Boston firm PureTech Development to help it find partners to develop and market its anti-bacterial furanone technology for pharmaceuticals, medical devices and implant applications in the US.

Uscom

Uscom (ASX:UCM) has won regulatory approval in Japan for its cardiac output devices. CEO Gary Davey said approval in Japan, the world's second-biggest market for medical devices, came two months ahead of schedule.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd